Oltipraz in the Prevention of Lung Cancer in People Who Smoke

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Northwestern University
ClinicalTrials.gov Identifier:
NCT00006457
First received: November 6, 2000
Last updated: June 7, 2012
Last verified: June 2012
  Purpose

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer.

PURPOSE: Randomized phase I trial to study the effectiveness of oltipraz in preventing lung cancer in people who smoke.


Condition Intervention Phase
Lung Cancer
Drug: oltipraz
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Clinical Phase I Multiple-Dose Safety Research Study of Oltipraz in Smokers

Resource links provided by NLM:


Further study details as provided by Northwestern University:

Study Start Date: August 2000
Study Completion Date: April 2004
Primary Completion Date: April 2004 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • Determine the effect of oltipraz on the level of BP-7,8-diol-9,10-epoxide (BPDE) DNA adducts in the lung lining cells (macrophages and bronchial epithelial cells) of smokers.
  • Determine the tolerability and toxicity of this treatment regimen in these patients.
  • Determine the effect of this treatment regimen on the level of macromolecule adducts in the blood (e.g., BPDE DNA, BPDE hemoglobin, and 8-hydroxy-deoxyguanine), oral lining cells (BPDE DNA), bladder lining cells (4-aminobiphenyl DNA), and lung macrophages (8-hydroxy-deoxyguanine) in these patients.
  • Determine the effect of this treatment regimen on the change (decrease) in activation of NNK as measured by change (increase) in urinary NNAL plus NNAL glucuronide in these patients.
  • Determine the effect of this treatment regimen on the oxidative state, glutathione-S-transferase activity, and superoxide dismutase 3 and phase II enzymes in the lungs and blood of these patients.
  • Compare the changes in oxidative state and phase II enzymes with changes in adduct levels in the lungs and blood of these patients.
  • Determine the correlation between oltipraz-induced changes in phase II enzymes and adduct formation with genotypic variation in glutathione-S-transferase isozymes in these patients.
  • Compare the response to this treatment regimen in terms of oxidative state, phase II enzymes, and adduct formation in the lungs vs the blood in these patients.

OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to participating center. Patients are randomized to one of three treatment arms.

  • Arm I: Patients receive an oral placebo weekly.
  • Arm II: Patients receive low-dose oral oltipraz weekly.
  • Arm III: Patients receive high-dose oral oltipraz weekly. Treatment continues for 12 weeks in the absence of unacceptable toxicity.

Patients are followed at 4 weeks.

PROJECTED ACCRUAL: A total of 66 patients (22 per treatment arm) will be accrued for this study within 21 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Current cigarette smokers

    • At least 20 cigarettes a day
    • No variation of more than 10 in the number of cigarettes smoked per day within the past 3 months
    • At least 10 years of smoking any amount
    • Failed to stop smoking after at least one attempt to quit within the last 3 years
  • Prior stage I non-small cell lung cancer allowed if surgically resected with at least a lobectomy
  • No concurrent evidence of lung cancer
  • Willing to undergo 2 bronchoscopies

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • ECOG 0

Life expectancy:

  • Not specified

Hematopoietic:

  • CBC normal
  • Hemostasis normal

Hepatic:

  • PT and PTT normal

Renal:

  • Blood chemistries normal
  • Nonfasting glucose no greater than 200 mg/dL
  • No active renal disease
  • No urinary tract infection by urinalysis (trace protein allowed)

Cardiovascular:

  • EKG normal
  • No coronary artery disease requiring continuous medication

Pulmonary:

  • Chest radiograph normal (postsurgical changes allowed)
  • No acute or significant chronic abnormality
  • FEV1 greater than 1.8 L or 75% predicted
  • No chronic obstructive pulmonary disease requiring continuous medication

Other:

  • No known hypersensitivity or prior adverse reaction to oltipraz
  • No inmates or prisoners
  • No medical or psychological condition that would preclude study (e.g., acute psychosis)
  • No prior malignancy except nonmelanomatous skin cancer, cervical dysplasia, or curatively treated stage I or II cancer of the head and neck
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 6 months after study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • At least 3 months since prior potential chemoprevention agent (e.g., oltipraz, retinoids, or acetylcysteine)

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Not specified

Surgery:

  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00006457

Locations
United States, Illinois
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States, 60611-3013
United States, North Carolina
Duke Comprehensive Cancer Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Northwestern University
Investigators
Study Chair: Raymond C. Bergan, MD Robert H. Lurie Cancer Center
  More Information

No publications provided

Responsible Party: Northwestern University
ClinicalTrials.gov Identifier: NCT00006457     History of Changes
Other Study ID Numbers: NCI 00L1, NU-00L1, DUMC-000346-00-2, NCI-P00-0167
Study First Received: November 6, 2000
Last Updated: June 7, 2012
Health Authority: United States: Federal Government

Keywords provided by Northwestern University:
non-small cell lung cancer
small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Oltipraz
Anthelmintics
Anti-Infective Agents
Anti-Retroviral Agents
Anticarcinogenic Agents
Antineoplastic Agents
Antiparasitic Agents
Antiplatyhelmintic Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Reverse Transcriptase Inhibitors
Schistosomicides
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014